TABLE OF CONTENTS TERMINOLOGIES AND DEFINITIONS GENERAL DATA AND SAFETY MONITORING AND OVERSIGHT STUDY DOCUMENTS NIAMS CLINICAL FUNDING OPPORTUNITIES, REVIEW AND AWARD ANCILLARY STUDIES HUMAN SUBJECTS AND CLINICAL TRIALS INFORMATION FORM CLINICALTRIALS.GOV TRAINING REQUIREMENTS FOR CLINICAL TRIALS

Up-to-date information about NIH funding, including all NIAMS-related programs and opportunities.

Learn NIAMS guidance and guidelines for studies that use internally-appointed monitoring for the oversight of NIAMS-funded clinical research. TABLE OF CONTENTS 1.0 Internally-appointed Monitoring 1.1 Roles and Responsibilities of the PI 1.2 Responsibilities of Internally-appointed Monitoring Body 1.2.a Internal Safety Monitoring Process 1.2.b Internal Review of Data and Safety Reports

The NIAMS Deputy Director page features information about Dr. Anna E. Mazzucco.

This is the Associate Director for Management and Operations and Executive Officer page, featuring Rick Phillips

Gayle Lester, Ph.D. Dr. Gayle Lester is director of the Division of Extramural Research (DER). Dr. Lester held the position in an acting role following the reorganization of the NIAMS extramural program in April 2018. She assumed the director position in March 2020. In addition to her programmatic management of

The Office of the Scientific Director (OSD) is responsible for oversight, review, and administration of the Intramural Research Program (IRP) at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The OSD has several key functions, including planning, coordinating, and directing the basic and clinical scientific research programs conducted within the IRP.

The Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program launched in 2021 with the goal of deepening our understanding of the cellular and molecular interactions that lead to inflammation and autoimmune diseases.

Overview While the success of antiretroviral therapies continues to improve the life expectancy of people living with HIV/AIDS (PLWHA), both aging and HIV-treatment are associated with the early appearance or greater risk of comorbidities that affect the musculoskeletal system and skin. In order to address the mechanisms underlying these changes